| Comprehensive review of molecular mechanisms and clinical features of invasive lobular cancer N Pramod, A Nigam, M Basree, R Mawalkar, S Mehra, N Shinde, ... The Oncologist 26 (6), e943-e953, 2021 | 44 | 2021 |
| Neutrophil-to-lymphocyte ratio as a predictor of immune checkpoint inhibitor therapy response in advanced bladder cancer. M Nair, S Dawsey, N Pramod, JR Clemenceau, TD Gilligan, MC Ornstein, ... Journal of Clinical Oncology 41 (16_suppl), e16586-e16586, 2023 | 2 | 2023 |
| IMPORTANCE OF PATHOLOGIC RE-REVIEW FOR PATIENTS WITH NON-MUSCLE-INVASIVE BLADDER CANCER–EVALUATING CHANGE IN GRADE, CLINICAL T STAGE AND RISK STRATIFICATION R Campbell, A Wood, P Michael, D Shin, N Pramod, SC Haywood, ... Urologic Oncology: Seminars and Original Investigations 42, S55-S56, 2024 | | 2024 |
| Effect of neutrophil to lymphocyte ratio (NLR) on outcomes with immune checkpoint inhibitors (ICIs) in patients (pts) with metastatic urothelial carcinoma (mUC) in real-world … D Lynn, S Dawsey, U Patgunarajah, N Pramod, W Wei, C Hobeika, M Nair, ... Journal of Clinical Oncology 42 (4_suppl), 678-678, 2024 | | 2024 |
| Effect of body mass index (BMI) on efficacy of immune checkpoint inhibitors (ICIs) in patients with metastatic urothelial carcinoma (mUC) in a real-world setting. D Lynn, C Hobeika, U Patgunarajah, S Dawsey, N Pramod, W Wei, M Nair, ... Journal of Clinical Oncology 42 (4_suppl), 571-571, 2024 | | 2024 |
| Factors predictive of primary resistance (PrimRes) to immune checkpoint inhibitors (ICIs) in patients (pts) with metastatic urothelial cancer (mUC). N Pramod, S Dawsey, U Patgunarajah, D Lynn, W Wei, C Hobeika, M Nair, ... Journal of Clinical Oncology 42 (4_suppl), 703-703, 2024 | | 2024 |
| Effect of type of antibiotics (Abx) on outcomes with immune checkpoint inhibitors (ICIs) in patients (pts) with metastatic urothelial carcinoma (mUC) in a real-world setting. C Hobeika, S Dawsey, U Patgunarajah, D Lynn, N Pramod, W Wei, M Nair, ... Journal of Clinical Oncology 42 (4_suppl), 640-640, 2024 | | 2024 |
| Genomic correlates of response and resistance to immune checkpoint inhibitors (ICI) in patients with metastatic urothelial carcinoma (mUC) in a real-world setting. N Pramod, V Makarov, S Dawsey, PG Pavicic, U Patgunarajah, M Nair, ... Journal of Clinical Oncology 42 (4_suppl), 670-670, 2024 | | 2024 |
| Characterizing immune-genomic signatures associated with response to immune checkpoint inhibitors (ICI) in patients with metastatic urothelial carcinoma (mUC). N Pramod, S Dawsey, PG Pavicic, R Lodha, U Patgunarajah, M Nair, ... Journal of Clinical Oncology 41 (16_suppl), e16582-e16582, 2023 | | 2023 |
| The effect of antibiotic (Abx) use on immune checkpoint inhibitor (ICI) efficacy in patients (pts) with metastatic urothelial carcinoma (mUC) in a real-world setting. U Patgunarajah, S Dawsey, N Pramod, K Maroli, MC Ornstein, CE Wee, ... Journal of Clinical Oncology 41 (16_suppl), 4580-4580, 2023 | | 2023 |
| Germline variant positive melanoma patients exhibit an enhanced inflammatory microenvironment A Shen, R Lodha, B Bungo, M Arbesman, N Pramod, J Ko, B Gastman, ... Cancer Research 83 (7_Supplement), 5963-5963, 2023 | | 2023 |
| Dissecting immuno-genomic pathways of response and resistance to immunotherapy in metastatic urothelial carcinoma in a real-world cohort N Pramod, P Pavicic, S Dawsey, A Shen, R Lodha, M Ornstein, O Mian, ... Cancer Research 83 (7_Supplement), 2278-2278, 2023 | | 2023 |
| Abstract P4-01-24: Targeting receptor tyrosine kinases in overcoming tamoxifen resistance and dormancy in invasive lobular cancer B Ramaswamy, N Pramod, A Kulkarni, XY Rima, E Reátegui, E Shankar, ... Cancer Research 83 (5_Supplement), P4-01-24-P4-01-24, 2023 | | 2023 |
| Abstract P1-18-22: Unlocking Her2 as a target in invasive lobular cancer and endocrine resistant invasive ductal carcinoma N Pramod, S Dhandayuthapani, S Majumder, B Ramaswamy Cancer Research 80 (4_Supplement), P1-18-22-P1-18-22, 2020 | | 2020 |
